BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 20962076)

  • 1. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.
    Brimacombe CL; Grove J; Meredith LW; Hu K; Syder AJ; Flores MV; Timpe JM; Krieger SE; Baumert TF; Tellinghuisen TL; Wong-Staal F; Balfe P; McKeating JA
    J Virol; 2011 Jan; 85(1):596-605. PubMed ID: 20962076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.
    Haberstroh A; Schnober EK; Zeisel MB; Carolla P; Barth H; Blum HE; Cosset FL; Koutsoudakis G; Bartenschlager R; Union A; Depla E; Owsianka A; Patel AH; Schuster C; Stoll-Keller F; Doffoël M; Dreux M; Baumert TF
    Gastroenterology; 2008 Nov; 135(5):1719-1728.e1. PubMed ID: 18718838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.
    Dreux M; Dao Thi VL; Fresquet J; Guérin M; Julia Z; Verney G; Durantel D; Zoulim F; Lavillette D; Cosset FL; Bartosch B
    PLoS Pathog; 2009 Feb; 5(2):e1000310. PubMed ID: 19229312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.
    Catanese MT; Loureiro J; Jones CT; Dorner M; von Hahn T; Rice CM
    J Virol; 2013 Aug; 87(15):8282-93. PubMed ID: 23698298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
    Bankwitz D; Vieyres G; Hueging K; Bitzegeio J; Doepke M; Chhatwal P; Haid S; Catanese MT; Zeisel MB; Nicosia A; Baumert TF; Kaderali L; Pietschmann T
    J Virol; 2014 Nov; 88(21):12644-55. PubMed ID: 25142595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus induces CD81 and claudin-1 endocytosis.
    Farquhar MJ; Hu K; Harris HJ; Davis C; Brimacombe CL; Fletcher SJ; Baumert TF; Rappoport JZ; Balfe P; McKeating JA
    J Virol; 2012 Apr; 86(8):4305-16. PubMed ID: 22318146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry.
    Hikosaka K; Noritake H; Kimura W; Sultana N; Sharkar MT; Tagawa Y; Uezato T; Kobayashi Y; Wakita T; Miura N
    Biomed Res; 2011 Apr; 32(2):143-50. PubMed ID: 21551950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cell polarization on hepatitis C virus entry.
    Mee CJ; Grove J; Harris HJ; Hu K; Balfe P; McKeating JA
    J Virol; 2008 Jan; 82(1):461-70. PubMed ID: 17959672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.
    Tong Y; Zhu Y; Xia X; Liu Y; Feng Y; Hua X; Chen Z; Ding H; Gao L; Wang Y; Feitelson MA; Zhao P; Qi ZT
    J Virol; 2011 Mar; 85(6):2793-802. PubMed ID: 21177818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetically humanized mouse model for hepatitis C virus infection.
    Dorner M; Horwitz JA; Robbins JB; Barry WT; Feng Q; Mu K; Jones CT; Schoggins JW; Catanese MT; Burton DR; Law M; Rice CM; Ploss A
    Nature; 2011 Jun; 474(7350):208-11. PubMed ID: 21654804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
    Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T
    PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Claudin association with CD81 defines hepatitis C virus entry.
    Harris HJ; Davis C; Mullins JG; Hu K; Goodall M; Farquhar MJ; Mee CJ; McCaffrey K; Young S; Drummer H; Balfe P; McKeating JA
    J Biol Chem; 2010 Jul; 285(27):21092-102. PubMed ID: 20375010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus infection of neuroepithelioma cell lines.
    Fletcher NF; Yang JP; Farquhar MJ; Hu K; Davis C; He Q; Dowd K; Ray SC; Krieger SE; Neyts J; Baumert TF; Balfe P; McKeating JA; Wong-Staal F
    Gastroenterology; 2010 Oct; 139(4):1365-74. PubMed ID: 20538002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process.
    Baktash Y; Madhav A; Coller KE; Randall G
    Cell Host Microbe; 2018 Mar; 23(3):382-394.e5. PubMed ID: 29544098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus receptor expression in normal and diseased liver tissue.
    Reynolds GM; Harris HJ; Jennings A; Hu K; Grove J; Lalor PF; Adams DH; Balfe P; Hübscher SG; McKeating JA
    Hepatology; 2008 Feb; 47(2):418-27. PubMed ID: 18085708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmission.
    Fofana I; Xiao F; Thumann C; Turek M; Zona L; Tawar RG; Grunert F; Thompson J; Zeisel MB; Baumert TF
    PLoS One; 2013; 8(5):e64221. PubMed ID: 23704981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.
    Krieger SE; Zeisel MB; Davis C; Thumann C; Harris HJ; Schnober EK; Mee C; Soulier E; Royer C; Lambotin M; Grunert F; Dao Thi VL; Dreux M; Cosset FL; McKeating JA; Schuster C; Baumert TF
    Hepatology; 2010 Apr; 51(4):1144-57. PubMed ID: 20069648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.
    Grove J; Nielsen S; Zhong J; Bassendine MF; Drummer HE; Balfe P; McKeating JA
    J Virol; 2008 Dec; 82(24):12020-9. PubMed ID: 18829747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.